Corrigan J J, Jeter M, Earnest D L
JAMA. 1982 Oct 8;248(14):1736-9.
Plasma levels of prothrombin immunoreactive protein (factor II antigen) (II-Ag) and coagulant activity (II-CA) were determined in eight patients with acute hepatitis and in 29 patients with chronic liver disease (cirrhosis). The II-CA was reduced in 23 (62%), II-Ag in 17 (46%), and both were reduced in 13 (36%) of the cases. A disproportionate reduction was noted in 21 (57%); ie, there was more II-Ag found in comparison to the corresponding level of II-Ca. Ninety-six percent (23) of 24 patients with moderate to severe hepatocellular disease showed reduced II-CA levels; 63% (15) showed reduced II-Ag levels, with a disproportionate reduction in II-CA in 67% (16). These data suggest that reduced synthesis as well as impaired carboxylation of prothrombin precursor protein are factors contributing to the coagulopathy in patients with moderate to severe liver disease and that measurement of circulating levels of II-Ag may provide an excellent indication of hepatic synthetic capacity.
测定了8例急性肝炎患者和29例慢性肝病（肝硬化）患者的血浆凝血酶原免疫反应蛋白（因子II抗原）（II-Ag）水平和凝血活性（II-CA）。23例（62%）患者的II-CA降低，17例（46%）患者的II-Ag降低，13例（36%）患者两者均降低。21例（57%）患者出现不成比例的降低；即与相应的II-Ca水平相比，发现的II-Ag更多。24例中度至重度肝细胞疾病患者中有96%（23例）的II-CA水平降低；63%（15例）的II-Ag水平降低，其中67%（16例）的II-CA出现不成比例的降低。这些数据表明，凝血酶原前体蛋白合成减少以及羧化受损是导致中度至重度肝病患者凝血功能障碍的因素，并且测定循环中的II-Ag水平可能是肝脏合成能力的一个很好的指标。
